MVM invests in MDxHealth SA

In May 2020, MVM closed a growth investment in MDxHealth SA, a company that markets proprietary, differentiated tests that optimize the care of patients with prostate cancer. MDxHealth’s two commercial tests, SelectMDx and ConfirmMDx, improve patient care and reduce costs by helping clinicians avoid unnecessary prostate biopsies.

MDxHealth will appoint Eric Bednarski as director of the company and Kyle Dempsey will join as a board observer.

Latest News

Valneva confirms participation in UK government COVID-19 vaccine response program

Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.

MVM invests in MDxHealth SA

MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.

MVM leads investment round in SkyCell

MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.

Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15

Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

MVM Partners LLP Closes Fund V

MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.